| Anti-idiotype antibody response after vaccination correlates with better overall survival in follicular lymphoma. | |
| | |
MedLine Citation:
|
PMID: 19346494 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Previous studies demonstrated that vaccination-induced tumor-specific immune response is associated with superior clinical outcome in patients with follicular lymphoma. Here, we investigated whether this positive correlation extends to overall survival (OS). We analyzed 91 untreated patients who received CVP chemotherapy (cyclophosphamide, vincristine, and prednisone) followed by idiotype vaccination. Idiotype proteins were produced either by the hybridoma method or by expression of recombinant idiotype-encoding sequences in mammalian or plant-based expression systems. We found that achieving a complete response/complete response unconfirmed (CR/CRu) to CVP and making an anti-idiotype antibody are 2 independent factors that each correlated with longer OS at 10 years (89% vs 68% with or without a CR/CRu, P = .024; 90% vs 69% with or without tumor-specific antibody production; P = .027). In the subset of patients who received hybridoma-generated vaccines, we found that anti-idiotype production was even more highly associated with superior OS (P < .002); this was the case even in patients with a partial response (PR) to CVP (P < .001). |
| | |
Authors:
|
Weiyun Z Ai; Robert Tibshirani; Behnaz Taidi; Debra Czerwinski; Ronald Levy |
Related Documents
:
|
20635974 - Dendritic-cell vaccination for prostate cancer. 15548714 - Immunological prevention of a multigene cancer syndrome. 16516674 - Future perspectives in the treatment of cutaneous t-cell lymphoma (ctcl). 10464704 - Enhanced antitumor immune responses of il-2 gene-modified tumor vaccine by combination ... 11855944 - Role of immune sera in the in-vitro phagocytosis of bordetella pertussis strains. 3399464 - Immunization of the elderly. a vital part of routine healthcare. |
Publication Detail:
|
Type: Journal Article; Research Support, N.I.H., Extramural Date: 2009-04-03 |
Journal Detail:
|
Title: Blood Volume: 113 ISSN: 1528-0020 ISO Abbreviation: Blood Publication Date: 2009 Jun |
Date Detail:
|
Created Date: 2009-06-05 Completed Date: 2009-07-27 Revised Date: 2010-09-22 |
Medline Journal Info:
|
Nlm Unique ID: 7603509 Medline TA: Blood Country: United States |
Other Details:
|
Languages: eng Pagination: 5743-6 Citation Subset: AIM; IM |
Affiliation:
|
Department of Medicine, Division of Hematology and Oncology, University of California, San Francisco, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Antibodies, Anti-Idiotypic
/
immunology* Antineoplastic Combined Chemotherapy Protocols / therapeutic use Cyclophosphamide / therapeutic use Follow-Up Studies Humans Immunotherapy* Lymphoma, Follicular / immunology*, therapy* Prednisone / therapeutic use Survival Rate Treatment Outcome Vaccination Vincristine / therapeutic use |
| Grant Support | |
ID/Acronym/Agency:
|
CA33399/CA/NCI NIH HHS; CA34233/CA/NCI NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Antibodies, Anti-Idiotypic; 0/COP protocol 2; 50-18-0/Cyclophosphamide; 53-03-2/Prednisone; 57-22-7/Vincristine |
| Comments/Corrections | |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: A shortcut to identifying small molecule signals that regulate behavior and development in Caenorhab...
Next Document: The transcriptional program controlled by the stem cell leukemia gene Scl/Tal1 during early embryoni...